This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Deal: Endo Health Acquires Paladin Labs in $1.6B Deal

NEW YORK ( The Deal) --  Endo Health Solutions (ENDP - Get Report) moved Tuesday, Nov. 5, to acquire Canada's Paladin Labs for $1.6 billion in stock and cash and hinted that more deals could be on the way to offset declining revenue from its core products.

Terms of the deal call for Malvern, Pa.-based Endo to pay C$77 for each Paladin share, a premium of 20% to the target's $63.91 Monday close. Holders of Paladin will receive 1.6331 shares of Endo plus C$1.16 in cash, plus one share of a new entity called Knight Therapeutics Inc. that will retain Paladin's product for the treatment of leishmaniasis, a parisitic disease carried by sand flies.

As part of the deal, both Endo and Paladin will formally be acquired by a new holding company, called New Endo, that will be domiciled in Ireland.

Montreal-based Paladin is a marketer of more than 60 drugs that treat ADHD, pain, urology issues and allergies, with operations in Canada and controlling stakes in ventures operating in Mexico and South Africa. Endo said that the deal would give it a strong platform in Canada and help offset sales pressure on its core painkiller drugs from generic competition, hinting that more deals could be on the way.

"The acquisition of Paladin Labs accelerates Endo's transformation from an integrated health solutions company to a top tier global specialty healthcare leader," Endo CEO Rajiv De Silva said in a statement. "Together with our sharpened focus, lean operating model and improved execution within our core businesses, strategic acquisitions will continue to play a key role in maximizing our growth potential and cash flow generation to drive future value for Endo shareholders."

Post-deal Endo will continue to be led by the company's current management team, with Paladin operating as a separate unit led by its current management and based in Montreal. Endo said it expects to extract at least $75 million in after tax annual savings savings from the deal which will leave current Endo shareholders with control of about 77.5% of the combination.

Paladin Chairman and founder Jonathan Ross Goodman in a statement said the deal "provides Paladin Labs shareholders an attractive current premium for their shares while allowing for ongoing participation in the upside potential of the combined company."

A Deutsche Bank Securities Inc. team including David Levin, Jason Haas, Michael Cohen and Jon Ohrn joined with Houlihan Lokey Financial Advisors Inc., Skadden Arps Slate Meagher & Flom LLP, Torys LLP and KPMG to serve as advisers to Endo, with Deutsche Bank and RBC Capital Markets agreeing to provide committed financing as part of the transaction. Credit Suisse, Davies Ward Phillips & Vineberg LLP and Ernst & Young advised Paladin.

By Lou Whiteman

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ENDP $28.13 0.00%
AAPL $95.18 0.00%
FB $117.43 0.00%
GOOG $692.36 0.00%
TSLA $232.32 0.00%


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs